ArticleProceedings of the National Academy of Sciences of the United States of America2003
Inhibition of herpes simplex virus 1 gene expression by designer zinc-finger transcription factors.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 73 citations in OpenAlex.
- A minimal region of the HSP90AB1 promoter is suitable for ubiquitous expression in different somatic tissues with applicability for gene therapy.Frontiers in molecular biosciences · 2023Article
- Integrated viral elements suggest the dual lifestyle ofVirus evolution · 2022Article
- Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.The CRISPR journal · 2021Article
- Recent developments and applications of genetic transformation and genome editing technologies in wheat.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2020Review
- Genome-Editing Technologies: Principles and Applications.Cold Spring Harbor perspectives in biology · 2016Review
- Transport and self-organization across different length scales powered by motor proteins and programmed by DNA.Nature nanotechnology · 2014Article
- Rationalizing the development of live attenuated virus vaccines.Nature biotechnology · 2010Review
- Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Negative regulation of the RTBV promoter by designed zinc finger proteins.Plant molecular biology · 2010Article
- Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA.Nature protocols · 2010Article
- Targeted inhibition of Snail family zinc finger transcription factors by oligonucleotide-Co(III) Schiff base conjugate.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Synthesis of programmable integrases.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA.Nucleic acids research · 2008Article
- Article
- The DNA binding domain of a papillomavirus E2 protein programs a chimeric nuclease to cleave integrated human papillomavirus DNA in HeLa cervical carcinoma cells.Journal of virology · 2007Article
- Chimeric DNA methyltransferases target DNA methylation to specific DNA sequences and repress expression of target genes.Nucleic acids research · 2007Article
- Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Inhibition of DNA replication of human papillomavirus by artificial zinc finger proteins.Journal of virology · 2006Article
- Gene repair: pointing the finger at genetic disease.Gene therapy · 2005Article
- Epigenetic manipulation of gene expression: a toolkit for cell biologists.The Journal of cell biology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The herpes simplex virus 1 (HSV-1) replicative cycle begins by binding of the viral activator, VP16, to a set of sequences in the immediate-early (IE) gene promoters. With the aim of inhibiting this cycle, we have constructed a number of synthetic zinc-finger DNA-binding peptides by using recently reported methods. Peptides containing either three or six fingers, targeted to a viral promoter, were engineered as fusions with a KOX-1 transcription repression domain. These proteins bound to the HSV-1 IE175k (ICP4) promoter, in vitro, with nanomolar or subnanomolar binding affinity. However, in a chloramphenicol acetyltransferase reporter system, only the six-finger protein was found to repress VP16-activated transcription significantly. Thus the longer array of zinc fingers is required to compete successfully against VP16, one of the most powerful natural activators known. We found that the HSV-1 replication cycle can be partially repressed by the six-finger peptide with the viral titer reduced by 90%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.